150521-32-7

Basic information

• Product Name: (S)-2-FORMYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: 2S-FORMYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;1-PIPERIDINECARBOXYLIC ACID, 2-FORMYL-,1,1-DIMETHYLETHYL ESTER(S);(S)-2-FORMYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;(S)-1-Boc-2-piperidinecarboxaldehyde;(S)-2-Formyl-1-piperidinecarboxylic acid tert-butyl ester;(S)-tert-butyl 2-formylpiperidine-1-carboxylate;1-Piperidinecarboxylic acid, 2-formyl-, 1,1-dimethylethyl ester, (2S)-;(2S)-2-Formylpiperidine, N-BOC protected
• CAS NO: 150521-32-7
• Molecular Formula: C₁₁H₁₉NO₃
• Molecular Weight: 213.27
• Mol File: 150521-32-7.mol

Chemical Properties

• Boiling Point: 295.431 °C at 760 mmHg
• Flash Point: 132.472 °C
• Appearance: /
• Density: 1.115 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -2.97±0.40(Predicted)
• CAS DataBase Reference: (S)-2-FORMYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-FORMYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(150521-32-7)
• EPA Substance Registry System: (S)-2-FORMYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(150521-32-7)

Safety Data

• Hazardous Substances Data: 150521-32-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(S)-2-FORMYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is used as a chemical intermediate for the synthesis of pharmaceutical compounds. Its unique functional groups and stereochemistry make it a valuable building block in the development of new drugs, contributing to the creation of molecules with specific therapeutic properties.
Used in Agrochemical Industry:
(S)-2-FORMYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is used as a chemical intermediate in the production of agrochemicals. Its versatility in chemical reactions allows for the synthesis of compounds with potential applications in crop protection, pest control, and other agricultural areas, enhancing the effectiveness of these products.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 203056-27-3 tert-butyl (2S)-2-{[methoxy(methyl)amino]-carbonyl}piperidine-1-carboxylate 
• 3105-95-1 pipecolinic acid 
• 675-20-7 piperidin-2-one 
• 85275-45-2 N-tert-butoxycarbonyl-3-piperidinol 
• 131667-57-7 tert-butyl 1,2,3,4-tetrahydro-1-pyridinecarboxylate 
• 86953-81-3 tert-butyl 2-hydroxypiperidine-1-carboxylate 
• 85908-96-9 2-oxopiperidine-1-carboxylic acid tert-butyl ester 
• 146337-23-7 tert-butyl 3-methoxypiperidine-1-carboxylate 
• 259133-67-0 2-carboxy-N-Boc-1,4,5,6-tetrahydropyridine 
• 157634-00-9 tert-butyl 2-(hydroxymethyl)piperidine-1-carboxylate 
• 75844-69-8 t-butyl piperidinecarboxylate 
• 68-12-2 N,N-dimethyl-formamide 
• 41373-39-1 (S)-pipecolinol 

Downstream Products

• 26250-84-0 (S)-(-)-1-(tert-butoxycarbonyl)-2-piperidinecarboxylic acid 
• 393827-07-1 (S)-2-vinyl-piperidine-1-carboxylic acid tert-butyl ester 
• 259133-72-7 (2R,6R)-2-Phenoxythiocarbonyloxymethyl-6-propyl-piperidine-1-carboxylic acid tert-butyl ester 
• 18881-13-5 (+)-coniceine 
• 139894-04-5 hexahydro-indolizin-3-one 
• 1027136-86-2 D-Pip-L-Pip-D-(N-Me)Phe-OCH₂Ph 
• 138775-25-4 L-Ile-D-Pip-L-Pip-D-(N-Me)Phe 
• 144073-29-0 Cbz-D-Phe-L-Ile-D-Pip-L-Pip-D-(N-Me)Phe 
• 138775-24-3 Fmoc-L-Ile-D-Pip-L-Pip-D-(N-Me)Phe-OCH₂Ph 
• 1094503-74-8 tert-butyl (2S)-2-{[3-(ethoxycarbonyl)phenyl](hydroxy)methyl}piperidine-1-carboxylate 
• 1214914-34-7 (S)-2-(2-oxo-propyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 639458-43-8 (S)-2-(2-oxo-ethyl)-piperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson’s Disease

Human indoleamine 2,3-dioxygenase 1 (hIDO1) and tryptophan 2,3-dioxygenase (hTDO) have been closely linked to the pathogenesis of Parkinson’s disease (PD); nevertheless, development of dual hIDO1 and hTDO inhibitors to evaluate their potential efficacy against PD is still lacking. Here, we report biochemical, biophysical, and computational analyses revealing that 1H-indazole-4-amines inhibit both hIDO1 and hTDO by a mechanism involving direct coordination with the heme ferrous and ferric states. Crystal structure-guided optimization led to23, which manifested IC50values of 0.64 and 0.04 μM to hIDO1 and hTDO, respectively, and had good pharmacokinetic properties and brain penetration in mice.23showed efficacy against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse motor coordination deficits, comparable to Madopar, an anti-PD medicine. Further studies revealed that different from Madopar,23likely has specific anti-PD mechanisms involving lowering IDO1 expression, alleviating dopaminergic neurodegeneration, reducing inflammatory cytokines and quinolinic acid in mouse brain, and increasing kynurenic acid in mouse blood.

Compound, preparation method thereof, pharmaceutical composition and application of compound

The invention discloses a compound, a preparation method thereof, a pharmaceutical composition and application of the compound. The compound I, and a stereoisomer or a pharmacologically acceptable salt thereof can serve as a CDK7 kinase inhibitor, are high in inhibition activity, and can be used for treatment of various malignant tumors.

COMPOUNDS, COMPOSITIONS AND METHODS FOR SYNTHESIS

The present disclosure, among other things, provides technologies for synthesis, including reagents and methods for stereoselective synthesis. In some embodiments, the present disclosure provides compounds useful as chiral auxiliaries. In some embodiments, the present disclosure provides reagents and methods for oligonucleotide synthesis. In some embodiments, the present disclosure provides reagents and methods for chirally controlled preparation of oligonucleotides. In some embodiments, technologies of the present disclosure are particularly useful for constructing challenging internucleotidic linkages, providing high yields and stereoselectivity.

Protecting-Group-Directed Regio- and Stereoselective Oxymercuration-Demercuration: Synthesis of Piperidine Alkaloids Containing 1,2- and 1,3-Amino Alcohol Units

An efficient synthesis of naturally occurring 1,2- and 1,3-amino alcohol unit containing 2-substituted piperidine alkaloids and their analogues has been developed from l -pipecolinic acid. The protocol describes the regio- and stereoselective oxymercuration-demercuration of 2-alkenyl piperidines based on protecting groups to give piperidine alkaloids as a key step.

As hepatitis c inhibitor spiro compound and its use in medicine

The invention provides a spiro compound serving as a hepatitis c inhibitor and application thereof in a medicine. The compound is a compound as shown in a formula (I) or a stereisomer, a geometric isomer, a tautomer, nitric oxide, an aquo-complex, a solvate, a metabolite, pharmaceutically acceptable salt or prodrug of the compound as shown in the formula (I). The invention also provides a pharmaceutical composition containing the compound, application of the compound and the pharmaceutical composition in inhibition of HCV (Hepatitis C Virus) copy and HCV virus protein, as well as the application of the compound and the pharmaceutical composition in prevention, handling, treatment or relieving of HCV infection or hepatitis c disease for a patient. The formula I is as shown in the specification.

Discovery and Total Synthesis of Streptoaminals: Antimicrobial [5,5]-Spirohemiaminals from the Combined-Culture of Streptomyces nigrescens and Tsukamurella pulmonis

A series of lipidic spirohemiaminals, designated streptoaminals, is reported. These were discovered by surveying the unique molecular signatures identified in the mass spectrometry data of the combined-culture broth of Streptomyces nigrescens HEK616 and T

COMPOUNDS AND USE FOR TREATING CANCER

The present invention relates to certain 2,4-disubstituted quinoline derivatives, to their therapy, as well as to pharmaceutical compositions comprising said compounds. More specifically the invention relates to certain 2,4-disubstituted quinoline derivatives or pharmaceutical compositions comprising said compounds for the treatment of cancers characterized by overactive Ras and/or Rac or signalling pathway.

Benzimidazole-2-piperazine compound, its pharmaceutical composition and its preparation and use

The invention relates to a benzimidazole-2-piperazine derivative and a preparing method and application of the benzimidazole-2-piperazine derivative in medicine, in particular to a novel benzimidazole-2-piperazine derivative shown in the general formula (I), a preparing method of the derivative, a pharmaceutical composition containing the derivative and application of the derivative serving as a therapeutic agent, especially serving as a poly (ADP-ribose) polymerase (PARP) inhibitor. In the general formula (I), R refers to hydrogen or halogen, G refers to carbonyl or methylene, m is 1-2, n is 1-3, and Q refers to hydrogen or C1-C4 alkyl. When X is methylene and Y is NR1 or methylene, X is NR1; R1 refers to hydrogen, C1-C6 alkyl, benzyl, COR2 or SO2R2; R2 refers to the following groups which are not substituted or groups substituted by 1-3 substituent groups, including C1-C6 alkyl, C3-C8 naphthenic base, phenyl, benzyl, naphthyl and C5-C10 aromatic heterocycle base, heterocycle in the C5-C10 aromatic heterocycle base comprises 1-3 heteroatoms selected from N, O and S, and the substituent groups are selected from the following atoms or groups of C1-C6 alkyl, C1-C6 alkoxy, halogen, amidogen, nitryl, sulfydryl, hydroxyl, cyanogroup and trifluoromethyl. The general formula (I) is shown in the specification.

Design and synthesis of fused tetrahydroisoquinoline-iminoimidazolines

In the aim of identifying new privileged structures, we describe the 5-steps synthesis of cyclic guanidine compounds "tetrahydroisoquinoline-iminoimidazolinesg" derived from tetrahydroisoquinoline-hydantoin core. In order to evaluate this new minimal structure and the impact of replacing a carbonyle by a guanidine moiety, their affinity towards adenosine receptor A2A was evaluated and compared to those of tetrahydroisoquinoline-hydantoin compounds.

A strategy for complex dimer formation when biomimicry fails: Total synthesis of ten coccinellid alkaloids

Although dimeric natural products can often be synthesized in the laboratory by directly merging advanced monomers, these approaches sometimes fail, leading instead to non-natural architectures via incorrect unions. Such a situation arose during our studies of the coccinellid alkaloids, when attempts to directly dimerize Natures presumed monomeric precursors in a putative biomimetic sequence afforded only a non-natural analogue through improper regiocontrol. Herein, we outline a unique strategy for dimer formation that obviates these difficulties, one which rapidly constructs the coccinellid dimers psylloborine A and isopsylloborine A through a terminating sequence of two reaction cascades that generate five bonds, five rings, and four stereocenters. In addition, a common synthetic intermediate is identified which allows for the rapid, asymmetric formal or complete total syntheses of eight monomeric members of the class.